Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study.
Authors:
- 1 April 1993
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 87 (4) , 1340-1353
Abstract
BACKGROUND: One of the side effects of interleukin 2 (IL-2) cancer immunotherapy in humans is the vascular leak syndrome, which is frequently associated with depression of myocardial function, myocarditis, and myocardial necrosis. METHODS AND RESULTS: To investigate this cardiotoxicity, IL-2 (three doses of 5 x 10(5) Cetus units/day i.p.) was given to rats for 2, 3, or 5 days. Heart, lung, liver, spleen, and kidney tissues were studied by light and electron microscopy and with immunoperoxidase techniques. Cardiac changes consisted of focal lymphocytic and eosinophilic infiltration, myocyte vacuolization, myofibrillar loss, and necrosis. Ultrastructural alterations included swelling of endothelial cells, with dissociation of intercellular junctions, migration of lymphocytes into the interstitium, and interstitial hemorrhage and edema. Close contact between infiltrating lymphocytes, particularly large granular lymphocytes, and cardiac myocytes was often observed in areas of tissue damage. All lesions were more severe on day 5 than on days 2 and 3. Immunoperoxidase stains demonstrated asialo GM1 ganglioside antibody-positive, granular lymphocytes to be much more frequent in myocardium of IL-2-treated rats than in that of control rats. CONCLUSIONS: Although we cannot exclude the possibility of a direct toxic effect of IL-2 on myocytes, our observations suggest that the myocardial damage produced by this agent is triggered by IL-2-activated lymphocytes that exert cytolytic effects, first on endothelial cells and then on cardiac myocytes, thus producing lesions that involve both the cardiac microcirculation and the muscle cells.Keywords
This publication has 37 references indexed in Scilit:
- Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancerCancer, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Mechanism of Cytotoxicity by Natural Killer (NK) CellsAnnual Review of Immunology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Electron-microscopic and immunohistochemical studies on endomyocardial biopsies from a patient with eosinophilic endomyocardial diseaseHeart and Vessels, 1985
- PHENOTYPE AND HISTOLOGICAL DISTRIBUTION OF INTERSTITIAL DENDRITIC CELLS IN THE RAT PANCREAS, LIVER, HEART, AND KIDNEYTransplantation, 1984
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- Two subsets of rat T lymphocytes defined with monoclonal antibodiesEuropean Journal of Immunology, 1980
- Ultrastructure of mammalian venous capillaries, venules, and small collecting veinsJournal of Ultrastructure Research, 1968